<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Medicine (Baltimore)</journal-id><journal-id journal-id-type="iso-abbrev">Medicine (Baltimore)</journal-id><journal-id journal-id-type="publisher-id">MEDI</journal-id><journal-title-group><journal-title>Medicine</journal-title></journal-title-group><issn pub-type="ppub">0025-7974</issn><issn pub-type="epub">1536-5964</issn><publisher><publisher-name>Wolters Kluwer Health</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29390463</article-id><article-id pub-id-type="pmc">5758165</article-id><article-id pub-id-type="publisher-id">MD-D-17-06846</article-id><article-id pub-id-type="doi">10.1097/MD.0000000000009194</article-id><article-id pub-id-type="art-access-id">09194</article-id><article-categories><subj-group subj-group-type="heading"><subject>5600</subject></subj-group><subj-group><subject>Research Article</subject><subject>Study Protocol Clinical Trial</subject></subj-group></article-categories><title-group><article-title>A double-blinded, randomized, placebo-controlled trial assessing the effects of nifedipine on embryo transfer</article-title><subtitle>Study protocol</subtitle></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ng</surname><given-names>Kelvin KL</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1"><sup>a</sup></xref><xref rid="cor1" ref-type="corresp"><sup>∗</sup></xref></contrib><contrib contrib-type="author"><name><surname>Rozen</surname><given-names>Genia</given-names></name><degrees>MBBS, MRMed</degrees><xref ref-type="aff" rid="aff2"><sup>b</sup></xref><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Stewart</surname><given-names>Tanya</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff2"><sup>b</sup></xref><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Agresta</surname><given-names>Franca</given-names></name><degrees>BSc, (Hons)</degrees><xref ref-type="aff" rid="aff2"><sup>b</sup></xref><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Polyakov</surname><given-names>Alex</given-names></name><degrees>MBBS, MSc</degrees><xref ref-type="aff" rid="aff2"><sup>b</sup></xref><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib></contrib-group><aff id="aff1"><label>a</label>Melbourne Medical School, University of Melbourne</aff><aff id="aff2"><label>b</label>Department of Reproductive Services, Royal Women's Hospital, Parkville</aff><aff id="aff3"><label>c</label>Melbourne IVF, East Melbourne, Victoria, Australia.</aff><author-notes id="cor1"><corresp><label>∗</label>Correspondence: Kelvin KL Ng, Melbourne Medical School, University of Melbourne, Parkville, 300 Grattan Street, Parkville, VIC 3052, Australia (e-mail: <email>kklng24@hotmail.com</email>).</corresp></author-notes><pub-date pub-type="collection"><month>12</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>22</day><month>12</month><year>2017</year></pub-date><volume>96</volume><issue>51</issue><elocation-id>e9194</elocation-id><history><date date-type="received"><day>7</day><month>11</month><year>2017</year></date><date date-type="accepted"><day>20</day><month>11</month><year>2017</year></date></history><permissions><copyright-statement>Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc.</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0"><license-p>This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link></license-p></license></permissions><self-uri xlink:type="simple" xlink:href="medi-96-e9194.pdf"></self-uri><abstract><title><offsets xml_i="4286" xml_f="4294" txt_i="11" txt_f="19">Abstract</offsets></title><sec sec-type="intro"><title><offsets xml_i="4331" xml_f="4344" txt_i="20" txt_f="33">Introduction:</offsets></title><p><offsets xml_i="4355" xml_f="5044" txt_i="34" txt_f="723">Implantation failure is the main factor affecting the success rate of in vitro fertilization (IVF) procedures. Studies have reported that uterine contractions (UCs) at the time of embryo transfer (ET) were inversely related to implantation and pregnancy rate, hence reducing the success of IVF treatment. Various pharmacological agents, with the exception of calcium channel blocker (CCB), have been investigated to reduce UC. In this regard, we are presenting a proposal for a double-blind randomized placebo-controlled trial. The trial aims to determine whether nifedipine, a CCB with potent smooth muscle relaxing activity and an excellent safety profile, can improve the outcome of ET.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="5085" xml_f="5106" txt_i="725" txt_f="746">Methods and analyses:</offsets></title><p><offsets xml_i="5117" xml_f="5663" txt_i="747" txt_f="1293">We will recruit 100 infertile women into one of 2 groups: placebo (n = 50) and nifedipine 20 mg (n = 50). Study participants will be admitted 30 minutes prior to ET and given either tablet after their baseline vital signs have been recorded. They will then undergo ET and be observed for adverse events for another 30 minutes post-ET. The primary outcome will be implantation rate and clinical pregnancy rate. Secondary outcomes include adverse events, miscarriage and pregnancy, and neonatal outcomes. Resulting data will then be analyzed using </offsets><italic><offsets xml_i="5671" xml_f="5672" txt_i="1293" txt_f="1294">t</offsets></italic><offsets xml_i="5681" xml_f="5880" txt_i="1294" txt_f="1493"> test, Chi-square test, and multivariate test to compare outcomes between the 2 groups for any statistical significance. This protocol has been designed in accordance with the SPIRIT 2013 Guidelines.</offsets></p></sec></abstract><kwd-group><title>Keywords</title><kwd>contraction</kwd><kwd>embryo transfer</kwd><kwd>IVF</kwd><kwd>nifedipine</kwd><kwd>uterus</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p><boxed-text position="float"><sec><title><offsets xml_i="6249" xml_f="6259" txt_i="1502" txt_f="1512">Key Points</offsets></title><p><list list-type="bullet"><list-item><p><offsets xml_i="6309" xml_f="6408" txt_i="1513" txt_f="1612">Significant preliminary research has been performed to form the basis for the design of this trial.</offsets></p></list-item><list-item><p><offsets xml_i="6438" xml_f="6572" txt_i="1613" txt_f="1747">This is a randomized, placebo-controlled, double-blind trial to assess nifedipine's effect and safety at the time of embryo transfers.</offsets></p></list-item><list-item><p><offsets xml_i="6602" xml_f="6700" txt_i="1748" txt_f="1846">This study has the potential to provide a foundation for future large randomized controlled trials</offsets></p></list-item><list-item><p><offsets xml_i="6730" xml_f="6827" txt_i="1847" txt_f="1944">This trial is a well-designed randomized controlled trial to assess clinically relevant outcomes.</offsets></p></list-item><list-item><p><offsets xml_i="6857" xml_f="6976" txt_i="1945" txt_f="2064">Main limitation of this study is that uterine contractions are not measured and existing variability in embryo quality.</offsets></p></list-item></list></p></sec></boxed-text></p><sec><label><offsets xml_i="7038" xml_f="7039" txt_i="2068" txt_f="2069">1</offsets></label><title><offsets xml_i="7054" xml_f="7066" txt_i="2069" txt_f="2081">Introduction</offsets></title><p><offsets xml_i="7077" xml_f="7598" txt_i="2082" txt_f="2603">Assisted reproduction technology (ART), from ovarian stimulation to the choice of catheters in embryo transfer (ET), has benefitted from major advances and improvements in recent years to continue to circumvent human infertility. However, implantation rate (IR) and clinical pregnancy rate (CPR) in women following ET have remained lower than desired. The IR and CPR are dependent on multiple factors such as techniques and materials involved in the ET process, quality of embryo, and also receptivity of the endometrium.</offsets><sup><offsets xml_i="7603" xml_f="7604" txt_i="2603" txt_f="2604">[</offsets><xref rid="R1" ref-type="bibr"><offsets xml_i="7635" xml_f="7636" txt_i="2604" txt_f="2605">1</offsets></xref><offsets xml_i="7643" xml_f="7644" txt_i="2605" txt_f="2606">]</offsets></sup><offsets xml_i="7650" xml_f="7823" txt_i="2606" txt_f="2779"> Extensive research has been undertaken to understand and to improve the success of ET following in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) cycles.</offsets></p><p><offsets xml_i="7830" xml_f="8016" txt_i="2780" txt_f="2966">One of the major limiting factors affecting the success of ET is thought to be the failure of embryo implantation in the uterus. Embryo implantation failure was estimated to be up to 85%</offsets><sup><offsets xml_i="8021" xml_f="8022" txt_i="2966" txt_f="2967">[</offsets><xref rid="R2" ref-type="bibr"><offsets xml_i="8053" xml_f="8054" txt_i="2967" txt_f="2968">2</offsets></xref><offsets xml_i="8061" xml_f="8062" txt_i="2968" txt_f="2969">]</offsets></sup><offsets xml_i="8068" xml_f="8167" txt_i="2969" txt_f="3068"> and is governed by complex mechanisms depending on the quality of both the embryo and endometrium.</offsets><sup><offsets xml_i="8172" xml_f="8173" txt_i="3068" txt_f="3069">[</offsets><xref rid="R3" ref-type="bibr"><offsets xml_i="8204" xml_f="8205" txt_i="3069" txt_f="3070">3</offsets></xref><offsets xml_i="8212" xml_f="8213" txt_i="3070" txt_f="3071">,</offsets><xref rid="R4" ref-type="bibr"><offsets xml_i="8244" xml_f="8245" txt_i="3071" txt_f="3072">4</offsets></xref><offsets xml_i="8252" xml_f="8253" txt_i="3072" txt_f="3073">]</offsets></sup></p><p><offsets xml_i="8266" xml_f="8377" txt_i="3074" txt_f="3185">Although embryonic aneuploidy is thought to be the major embryonic limiting factor for successful implantation,</offsets><sup><offsets xml_i="8382" xml_f="8383" txt_i="3185" txt_f="3186">[</offsets><xref rid="R3" ref-type="bibr"><offsets xml_i="8414" xml_f="8415" txt_i="3186" txt_f="3187">3</offsets></xref><offsets xml_i="8422" xml_f="8423" txt_i="3187" txt_f="3188">]</offsets></sup><offsets xml_i="8429" xml_f="8570" txt_i="3188" txt_f="3329"> excessive uterine contractions (UCs) has been proposed as the endometrial limiting factor contributing to the reduced IR in IVF/ICSI cycles.</offsets><sup><offsets xml_i="8575" xml_f="8576" txt_i="3329" txt_f="3330">[</offsets><xref rid="R3" ref-type="bibr"><offsets xml_i="8607" xml_f="8608" txt_i="3330" txt_f="3331">3</offsets></xref><offsets xml_i="8615" xml_f="8616" txt_i="3331" txt_f="3332">–</offsets><xref rid="R5" ref-type="bibr"><offsets xml_i="8647" xml_f="8648" txt_i="3332" txt_f="3333">5</offsets></xref><offsets xml_i="8655" xml_f="8656" txt_i="3333" txt_f="3334">]</offsets></sup><offsets xml_i="8662" xml_f="8792" txt_i="3334" txt_f="3464"> As contractile or peristaltic activities of the uterus could move the implanted embryo toward the fallopian tube or cervix/vagina</offsets><sup><offsets xml_i="8797" xml_f="8798" txt_i="3464" txt_f="3465">[</offsets><xref rid="R6" ref-type="bibr"><offsets xml_i="8829" xml_f="8830" txt_i="3465" txt_f="3466">6</offsets></xref><offsets xml_i="8837" xml_f="8838" txt_i="3466" txt_f="3467">]</offsets></sup><offsets xml_i="8844" xml_f="8897" txt_i="3467" txt_f="3520"> or might even expel it completely out of the uterus.</offsets><sup><offsets xml_i="8902" xml_f="8903" txt_i="3520" txt_f="3521">[</offsets><xref rid="R3" ref-type="bibr"><offsets xml_i="8934" xml_f="8935" txt_i="3521" txt_f="3522">3</offsets></xref><offsets xml_i="8942" xml_f="8943" txt_i="3522" txt_f="3523">,</offsets><xref rid="R4" ref-type="bibr"><offsets xml_i="8974" xml_f="8975" txt_i="3523" txt_f="3524">4</offsets></xref><offsets xml_i="8982" xml_f="8983" txt_i="3524" txt_f="3525">]</offsets></sup><offsets xml_i="8989" xml_f="9123" txt_i="3525" txt_f="3659"> This peristaltic mechanism toward the fallopian tube has been suggested to be the cause of higher ectopic pregnancy rate seen in ART.</offsets><sup><offsets xml_i="9128" xml_f="9129" txt_i="3659" txt_f="3660">[</offsets><xref rid="R6" ref-type="bibr"><offsets xml_i="9160" xml_f="9161" txt_i="3660" txt_f="3661">6</offsets></xref><offsets xml_i="9168" xml_f="9169" txt_i="3661" txt_f="3662">,</offsets><xref rid="R7" ref-type="bibr"><offsets xml_i="9200" xml_f="9201" txt_i="3662" txt_f="3663">7</offsets></xref><offsets xml_i="9208" xml_f="9209" txt_i="3663" txt_f="3664">]</offsets></sup><offsets xml_i="9215" xml_f="9371" txt_i="3664" txt_f="3820"> A recent published study demonstrated that the uterine peristaltic wave frequency before ET was inversely related to CPR in fresh and frozen–thawed cycles.</offsets><sup><offsets xml_i="9376" xml_f="9377" txt_i="3820" txt_f="3821">[</offsets><xref rid="R7" ref-type="bibr"><offsets xml_i="9408" xml_f="9409" txt_i="3821" txt_f="3822">7</offsets></xref><offsets xml_i="9416" xml_f="9417" txt_i="3822" txt_f="3823">]</offsets></sup></p><p><offsets xml_i="9430" xml_f="9656" txt_i="3824" txt_f="4050">Various pharmacological agents have been investigated to reduce UC since. These include cyclo-oxygenase inhibitors, β2 adrenoreceptor agonists, antiinflammatories, phosphodiesterase inhibitors, progesterone, and antispasmodics</offsets><sup><offsets xml_i="9661" xml_f="9662" txt_i="4050" txt_f="4051">[</offsets><xref rid="R8" ref-type="bibr"><offsets xml_i="9693" xml_f="9694" txt_i="4051" txt_f="4052">8</offsets></xref><offsets xml_i="9701" xml_f="9702" txt_i="4052" txt_f="4053">–</offsets><xref rid="R23" ref-type="bibr"><offsets xml_i="9734" xml_f="9736" txt_i="4053" txt_f="4055">23</offsets></xref><offsets xml_i="9743" xml_f="9744" txt_i="4055" txt_f="4056">]</offsets></sup><offsets xml_i="9750" xml_f="9897" txt_i="4056" txt_f="4203"> demonstrating variable results. Atosiban, an oxytocin/vasopressin receptor antagonist, has shown to be the most promising in improving IR and CPR.</offsets><sup><offsets xml_i="9902" xml_f="9903" txt_i="4203" txt_f="4204">[</offsets><xref rid="R13" ref-type="bibr"><offsets xml_i="9935" xml_f="9937" txt_i="4204" txt_f="4206">13</offsets></xref><offsets xml_i="9944" xml_f="9945" txt_i="4206" txt_f="4207">]</offsets></sup></p><p><offsets xml_i="9958" xml_f="10144" txt_i="4208" txt_f="4394">If excessive UC indeed reduces IR and CPR in women undergoing IVF/ICSI cycles, then it represents a potential target for pharmacological agents to improve the success of IVF/ICSI cycles.</offsets></p><p><offsets xml_i="10151" xml_f="10383" txt_i="4395" txt_f="4627">Calcium channel blockers (CCBs) are nonspecific smooth muscle relaxants, predominantly used for the treatment of hypertension in adults. It specifically inhibits the transmembrane calcium influx at the voltage-gated L-type channels.</offsets><sup><offsets xml_i="10388" xml_f="10389" txt_i="4627" txt_f="4628">[</offsets><xref rid="R24" ref-type="bibr"><offsets xml_i="10421" xml_f="10423" txt_i="4628" txt_f="4630">24</offsets></xref><offsets xml_i="10430" xml_f="10431" txt_i="4630" txt_f="4631">]</offsets></sup><offsets xml_i="10437" xml_f="10609" txt_i="4631" txt_f="4803"> Since these channels are expressed widely throughout body, including the myocardial cells, vasculature smooth muscles, and the myometrium, CCB exhibits multiorgan effects.</offsets><sup><offsets xml_i="10614" xml_f="10615" txt_i="4803" txt_f="4804">[</offsets><xref rid="R25" ref-type="bibr"><offsets xml_i="10647" xml_f="10649" txt_i="4804" txt_f="4806">25</offsets></xref><offsets xml_i="10656" xml_f="10657" txt_i="4806" txt_f="4807">]</offsets></sup><offsets xml_i="10663" xml_f="10775" txt_i="4807" txt_f="4919"> By inhibiting the slow inward current of the action potential via reducing the intracellular levels of calcium,</offsets><sup><offsets xml_i="10780" xml_f="10781" txt_i="4919" txt_f="4920">[</offsets><xref rid="R26" ref-type="bibr"><offsets xml_i="10813" xml_f="10815" txt_i="4920" txt_f="4922">26</offsets></xref><offsets xml_i="10822" xml_f="10823" txt_i="4922" txt_f="4923">]</offsets></sup><offsets xml_i="10829" xml_f="10972" txt_i="4923" txt_f="5066"> it decreases the contractility of the smooth muscles and hence causes vasodilation, uterine relaxation, and other effects throughout the body.</offsets><sup><offsets xml_i="10977" xml_f="10978" txt_i="5066" txt_f="5067">[</offsets><xref rid="R24" ref-type="bibr"><offsets xml_i="11010" xml_f="11012" txt_i="5067" txt_f="5069">24</offsets></xref><offsets xml_i="11019" xml_f="11020" txt_i="5069" txt_f="5070">]</offsets></sup></p><p><offsets xml_i="11033" xml_f="11131" txt_i="5071" txt_f="5169">The most widely used and studied CCB is nifedipine, and there is evidence for safety in pregnancy.</offsets><sup><offsets xml_i="11136" xml_f="11137" txt_i="5169" txt_f="5170">[</offsets><xref rid="R27" ref-type="bibr"><offsets xml_i="11169" xml_f="11171" txt_i="5170" txt_f="5172">27</offsets></xref><offsets xml_i="11178" xml_f="11179" txt_i="5172" txt_f="5173">–</offsets><xref rid="R31" ref-type="bibr"><offsets xml_i="11211" xml_f="11213" txt_i="5173" txt_f="5175">31</offsets></xref><offsets xml_i="11220" xml_f="11221" txt_i="5175" txt_f="5176">]</offsets></sup><offsets xml_i="11227" xml_f="11359" txt_i="5176" txt_f="5308"> Nifedipine belongs to a subclass of CCB, namely dihydropyridine, which is selective to vascular over cardiac tissues of about 10:1.</offsets><sup><offsets xml_i="11364" xml_f="11365" txt_i="5308" txt_f="5309">[</offsets><xref rid="R27" ref-type="bibr"><offsets xml_i="11397" xml_f="11399" txt_i="5309" txt_f="5311">27</offsets></xref><offsets xml_i="11406" xml_f="11407" txt_i="5311" txt_f="5312">]</offsets></sup><offsets xml_i="11413" xml_f="11494" txt_i="5312" txt_f="5393"> Nifedipine, as a CCB, has vasodilatory and potent uterine relaxation properties.</offsets><sup><offsets xml_i="11499" xml_f="11500" txt_i="5393" txt_f="5394">[</offsets><xref rid="R24" ref-type="bibr"><offsets xml_i="11532" xml_f="11534" txt_i="5394" txt_f="5396">24</offsets></xref><offsets xml_i="11541" xml_f="11542" txt_i="5396" txt_f="5397">]</offsets></sup><offsets xml_i="11548" xml_f="11815" txt_i="5397" txt_f="5664"> It appears that nifedipine is a very safe drug with limited major adverse effects and has demonstrated superiority over other drugs, such as labetolol and β2 adrenoreceptor agonists, in the management of preterm labour or pregnancy induced hypertension consistently.</offsets><sup><offsets xml_i="11820" xml_f="11821" txt_i="5664" txt_f="5665">[</offsets><xref rid="R24" ref-type="bibr"><offsets xml_i="11853" xml_f="11855" txt_i="5665" txt_f="5667">24</offsets></xref><offsets xml_i="11862" xml_f="11863" txt_i="5667" txt_f="5668">,</offsets><xref rid="R27" ref-type="bibr"><offsets xml_i="11895" xml_f="11897" txt_i="5668" txt_f="5670">27</offsets></xref><offsets xml_i="11904" xml_f="11905" txt_i="5670" txt_f="5671">–</offsets><xref rid="R29" ref-type="bibr"><offsets xml_i="11937" xml_f="11939" txt_i="5671" txt_f="5673">29</offsets></xref><offsets xml_i="11946" xml_f="11947" txt_i="5673" txt_f="5674">,</offsets><xref rid="R32" ref-type="bibr"><offsets xml_i="11979" xml_f="11981" txt_i="5674" txt_f="5676">32</offsets></xref><offsets xml_i="11988" xml_f="11989" txt_i="5676" txt_f="5677">–</offsets><xref rid="R37" ref-type="bibr"><offsets xml_i="12021" xml_f="12023" txt_i="5677" txt_f="5679">37</offsets></xref><offsets xml_i="12030" xml_f="12031" txt_i="5679" txt_f="5680">]</offsets></sup></p><p><offsets xml_i="12044" xml_f="12113" txt_i="5681" txt_f="5750">As nifedipine is an antihypertensive and has cardiodepressive effect,</offsets><sup><offsets xml_i="12118" xml_f="12119" txt_i="5750" txt_f="5751">[</offsets><xref rid="R38" ref-type="bibr"><offsets xml_i="12151" xml_f="12153" txt_i="5751" txt_f="5753">38</offsets></xref><offsets xml_i="12160" xml_f="12161" txt_i="5753" txt_f="5754">]</offsets></sup><offsets xml_i="12167" xml_f="12291" txt_i="5754" txt_f="5878"> patients who suffer from hypotensive or compromised cardiovascular conditions are contraindicated to the use of nifedipine.</offsets><sup><offsets xml_i="12296" xml_f="12297" txt_i="5878" txt_f="5879">[</offsets><xref rid="R34" ref-type="bibr"><offsets xml_i="12329" xml_f="12331" txt_i="5879" txt_f="5881">34</offsets></xref><offsets xml_i="12338" xml_f="12339" txt_i="5881" txt_f="5882">]</offsets></sup><offsets xml_i="12345" xml_f="12632" txt_i="5882" txt_f="6169"> For others, the most common maternal side effects, when nifedipine is used in a therapeutic range, are: transient facial flushing, headache, nausea, tachycardia, and hypotension; less common side effects are: palpitations, dizziness, chest pain, nasal congestion, oedema, and heartburn.</offsets><sup><offsets xml_i="12637" xml_f="12638" txt_i="6169" txt_f="6170">[</offsets><xref rid="R25" ref-type="bibr"><offsets xml_i="12670" xml_f="12672" txt_i="6170" txt_f="6172">25</offsets></xref><offsets xml_i="12679" xml_f="12680" txt_i="6172" txt_f="6173">,</offsets><xref rid="R28" ref-type="bibr"><offsets xml_i="12712" xml_f="12714" txt_i="6173" txt_f="6175">28</offsets></xref><offsets xml_i="12721" xml_f="12722" txt_i="6175" txt_f="6176">,</offsets><xref rid="R37" ref-type="bibr"><offsets xml_i="12754" xml_f="12756" txt_i="6176" txt_f="6178">37</offsets></xref><offsets xml_i="12763" xml_f="12764" txt_i="6178" txt_f="6179">,</offsets><xref rid="R39" ref-type="bibr"><offsets xml_i="12796" xml_f="12798" txt_i="6179" txt_f="6181">39</offsets></xref><offsets xml_i="12805" xml_f="12806" txt_i="6181" txt_f="6182">–</offsets><xref rid="R40" ref-type="bibr"><offsets xml_i="12838" xml_f="12840" txt_i="6182" txt_f="6184">40</offsets></xref><offsets xml_i="12847" xml_f="12848" txt_i="6184" txt_f="6185">]</offsets></sup><offsets xml_i="12854" xml_f="12958" txt_i="6185" txt_f="6289"> These side effects are mostly benign and are resolved spontaneously or by withdrawal of administration.</offsets><sup><offsets xml_i="12963" xml_f="12964" txt_i="6289" txt_f="6290">[</offsets><xref rid="R37" ref-type="bibr"><offsets xml_i="12996" xml_f="12998" txt_i="6290" txt_f="6292">37</offsets></xref><offsets xml_i="13005" xml_f="13006" txt_i="6292" txt_f="6293">,</offsets><xref rid="R39" ref-type="bibr"><offsets xml_i="13038" xml_f="13040" txt_i="6293" txt_f="6295">39</offsets></xref><offsets xml_i="13047" xml_f="13048" txt_i="6295" txt_f="6296">–</offsets><xref rid="R40" ref-type="bibr"><offsets xml_i="13080" xml_f="13082" txt_i="6296" txt_f="6298">40</offsets></xref><offsets xml_i="13089" xml_f="13090" txt_i="6298" txt_f="6299">]</offsets></sup><offsets xml_i="13096" xml_f="13169" txt_i="6299" txt_f="6372"> Naturally, adverse events vary according to the total dose of nifedipine</offsets><sup><offsets xml_i="13174" xml_f="13175" txt_i="6372" txt_f="6373">[</offsets><xref rid="R28" ref-type="bibr"><offsets xml_i="13207" xml_f="13209" txt_i="6373" txt_f="6375">28</offsets></xref><offsets xml_i="13216" xml_f="13217" txt_i="6375" txt_f="6376">]</offsets></sup><offsets xml_i="13223" xml_f="13396" txt_i="6376" txt_f="6549"> and these data arise from studies based on multiple dosing regimen but no data are available for a single dose regimen. Current recommended maximum dosage is 120 mg per day</offsets><sup><offsets xml_i="13401" xml_f="13402" txt_i="6549" txt_f="6550">[</offsets><xref rid="R31" ref-type="bibr"><offsets xml_i="13434" xml_f="13436" txt_i="6550" txt_f="6552">31</offsets></xref><offsets xml_i="13443" xml_f="13444" txt_i="6552" txt_f="6553">]</offsets></sup><offsets xml_i="13450" xml_f="13578" txt_i="6553" txt_f="6681"> but maximum dose of 160 mg per day has been reported to achieve tocolysis with no increase in maternal side effects in 1 study.</offsets><sup><offsets xml_i="13583" xml_f="13584" txt_i="6681" txt_f="6682">[</offsets><xref rid="R41" ref-type="bibr"><offsets xml_i="13616" xml_f="13618" txt_i="6682" txt_f="6684">41</offsets></xref><offsets xml_i="13625" xml_f="13626" txt_i="6684" txt_f="6685">]</offsets></sup><offsets xml_i="13632" xml_f="13732" txt_i="6685" txt_f="6785"> Nevertheless, caution should be exercised when prescribing any medication in any clinical scenario.</offsets></p><p><offsets xml_i="13739" xml_f="13822" txt_i="6786" txt_f="6869">There is currently no evidence to demonstrate nifedipine toxicity on human embryos.</offsets><sup><offsets xml_i="13827" xml_f="13828" txt_i="6869" txt_f="6870">[</offsets><xref rid="R42" ref-type="bibr"><offsets xml_i="13860" xml_f="13862" txt_i="6870" txt_f="6872">42</offsets></xref><offsets xml_i="13869" xml_f="13870" txt_i="6872" txt_f="6873">–</offsets><xref rid="R46" ref-type="bibr"><offsets xml_i="13902" xml_f="13904" txt_i="6873" txt_f="6875">46</offsets></xref><offsets xml_i="13911" xml_f="13912" txt_i="6875" txt_f="6876">]</offsets></sup><offsets xml_i="13918" xml_f="14141" txt_i="6876" txt_f="7099"> More importantly, a long-term study following 94 neonates for up to 18 months of life has found no impact on malformations, diseases incidences, motor function, or childhood education following nifedipine exposure in utero</offsets><sup><offsets xml_i="14146" xml_f="14147" txt_i="7099" txt_f="7100">[</offsets><xref rid="R47" ref-type="bibr"><offsets xml_i="14179" xml_f="14181" txt_i="7100" txt_f="7102">47</offsets></xref><offsets xml_i="14188" xml_f="14189" txt_i="7102" txt_f="7103">]</offsets></sup><offsets xml_i="14195" xml_f="14288" txt_i="7103" txt_f="7196"> while another large case–control study also found no increased in congenital anomalies risk.</offsets><sup><offsets xml_i="14293" xml_f="14294" txt_i="7196" txt_f="7197">[</offsets><xref rid="R48" ref-type="bibr"><offsets xml_i="14326" xml_f="14328" txt_i="7197" txt_f="7199">48</offsets></xref><offsets xml_i="14335" xml_f="14336" txt_i="7199" txt_f="7200">]</offsets></sup><offsets xml_i="14342" xml_f="14540" txt_i="7200" txt_f="7398"> Improved neonatal outcomes, such as neonatal morbidity, have also been demonstrated over other tocolytics and antihypertensives in the treatment of pregnancy induced hypertension and preterm labor.</offsets><sup><offsets xml_i="14545" xml_f="14546" txt_i="7398" txt_f="7399">[</offsets><xref rid="R28" ref-type="bibr"><offsets xml_i="14578" xml_f="14580" txt_i="7399" txt_f="7401">28</offsets></xref><offsets xml_i="14587" xml_f="14588" txt_i="7401" txt_f="7402">,</offsets><xref rid="R32" ref-type="bibr"><offsets xml_i="14620" xml_f="14622" txt_i="7402" txt_f="7404">32</offsets></xref><offsets xml_i="14629" xml_f="14630" txt_i="7404" txt_f="7405">,</offsets><xref rid="R36" ref-type="bibr"><offsets xml_i="14662" xml_f="14664" txt_i="7405" txt_f="7407">36</offsets></xref><offsets xml_i="14671" xml_f="14672" txt_i="7407" txt_f="7408">,</offsets><xref rid="R49" ref-type="bibr"><offsets xml_i="14704" xml_f="14706" txt_i="7408" txt_f="7410">49</offsets></xref><offsets xml_i="14713" xml_f="14714" txt_i="7410" txt_f="7411">,</offsets><xref rid="R50" ref-type="bibr"><offsets xml_i="14746" xml_f="14748" txt_i="7411" txt_f="7413">50</offsets></xref><offsets xml_i="14755" xml_f="14756" txt_i="7413" txt_f="7414">–</offsets><xref rid="R56" ref-type="bibr"><offsets xml_i="14788" xml_f="14790" txt_i="7414" txt_f="7416">56</offsets></xref><offsets xml_i="14797" xml_f="14798" txt_i="7416" txt_f="7417">]</offsets></sup></p></sec><sec><label><offsets xml_i="14826" xml_f="14827" txt_i="7419" txt_f="7420">2</offsets></label><title><offsets xml_i="14842" xml_f="14851" txt_i="7420" txt_f="7429">Rationale</offsets></title><p><offsets xml_i="14862" xml_f="15473" txt_i="7430" txt_f="8041">Implantation failure remains a major factor affecting the success rate of IVF treatment. There is enough evidence to demonstrate that excessive uterine activities are detrimental to the outcome of ET. Given nifedipine's potent uterine relaxing properties and excellent safety profile, it is a promising candidate to improve IVF outcomes. There is a dearth of information in the literature regarding the use of nifedipine in ART. Therefore, the objective of this study is to evaluate the efficacy of nifedipine administration in improving implantation and pregnancy rates in IVF/ICSI fresh and frozen–thawed ETs.</offsets></p></sec><sec><label><offsets xml_i="15495" xml_f="15496" txt_i="8043" txt_f="8044">3</offsets></label><title><offsets xml_i="15511" xml_f="15515" txt_i="8044" txt_f="8048">AIMS</offsets></title><p><offsets xml_i="15526" xml_f="15665" txt_i="8049" txt_f="8188">We aim to establish the clinical benefit and other outcomes of ET from a single-dose nifedipine administration as a smooth muscle relaxant.</offsets></p><p><offsets xml_i="15672" xml_f="15694" txt_i="8189" txt_f="8211">Specific outcomes are:</offsets><list list-type="simple"><list-item><label><offsets xml_i="15737" xml_f="15740" txt_i="8211" txt_f="8214">(1)</offsets></label><p><offsets xml_i="15751" xml_f="15753" txt_i="8214" txt_f="8216">IR</offsets></p></list-item><list-item><label><offsets xml_i="15787" xml_f="15790" txt_i="8217" txt_f="8220">(2)</offsets></label><p><offsets xml_i="15801" xml_f="15804" txt_i="8220" txt_f="8223">CPR</offsets></p></list-item><list-item><label><offsets xml_i="15838" xml_f="15841" txt_i="8224" txt_f="8227">(3)</offsets></label><p><offsets xml_i="15852" xml_f="15895" txt_i="8227" txt_f="8270">Adverse events rate, including miscarriages</offsets></p></list-item><list-item><label><offsets xml_i="15929" xml_f="15932" txt_i="8271" txt_f="8274">(4)</offsets></label><p><offsets xml_i="15943" xml_f="15958" txt_i="8274" txt_f="8289">Live birth rate</offsets></p></list-item><list-item><label><offsets xml_i="15992" xml_f="15995" txt_i="8290" txt_f="8293">(5)</offsets></label><p><offsets xml_i="16006" xml_f="16037" txt_i="8293" txt_f="8324">Pregnancy and neonatal outcomes</offsets></p></list-item></list></p></sec><sec><label><offsets xml_i="16082" xml_f="16083" txt_i="8327" txt_f="8328">4</offsets></label><title><offsets xml_i="16098" xml_f="16118" txt_i="8328" txt_f="8348">Methods and analyses</offsets></title><p><offsets xml_i="16129" xml_f="16552" txt_i="8349" txt_f="8772">This protocol has been designed in accordance with the SPIRIT 2013 Guidelines. Recruitment will start from the end of 2016 for approximately 12 months. Analysis and dissemination will occur after this period of time. Analysis will be by intention to treat and the study is to expect to be completed by the beginning of 2018, approximately the 1st of February 2018, with all live births and secondary outcomes data analyzed.</offsets></p></sec><sec><label><offsets xml_i="16574" xml_f="16575" txt_i="8774" txt_f="8775">5</offsets></label><title><offsets xml_i="16590" xml_f="16602" txt_i="8775" txt_f="8787">Study design</offsets></title><p><offsets xml_i="16613" xml_f="16687" txt_i="8788" txt_f="8862">Interventional phase I double-blinded randomized placebo-controlled trial.</offsets></p></sec><sec><label><offsets xml_i="16709" xml_f="16710" txt_i="8864" txt_f="8865">6</offsets></label><title><offsets xml_i="16725" xml_f="16737" txt_i="8865" txt_f="8877">Participants</offsets></title><p><offsets xml_i="16748" xml_f="16821" txt_i="8878" txt_f="8951">We plan to recruit 100 infertile women undergoing ETs in IVF/ICSI cycles.</offsets></p></sec><sec><label><offsets xml_i="16843" xml_f="16844" txt_i="8953" txt_f="8954">7</offsets></label><title><offsets xml_i="16859" xml_f="16872" txt_i="8954" txt_f="8967">Study setting</offsets></title><p><offsets xml_i="16883" xml_f="17057" txt_i="8968" txt_f="9142">Patients will be recruited from Melbourne IVF over a period of 12 months. This should allow enough time to achieve adequate participant enrolment to reach target sample size.</offsets></p></sec><sec><label><offsets xml_i="17079" xml_f="17080" txt_i="9144" txt_f="9145">8</offsets></label><title><offsets xml_i="17095" xml_f="17123" txt_i="9145" txt_f="9173">Interventions to be measured</offsets></title><p><offsets xml_i="17134" xml_f="17218" txt_i="9174" txt_f="9258">This trial will have 2 arms. All capsules will be indistinguishable from each other.</offsets><list list-type="simple"><list-item><label><offsets xml_i="17261" xml_f="17264" txt_i="9258" txt_f="9261">(1)</offsets></label><p><offsets xml_i="17275" xml_f="17320" txt_i="9261" txt_f="9306">Placebo tablet taken once, 30 minutes pre-ET.</offsets></p></list-item><list-item><label><offsets xml_i="17354" xml_f="17357" txt_i="9307" txt_f="9310">(2)</offsets></label><p><offsets xml_i="17368" xml_f="17439" txt_i="9310" txt_f="9381">20 mg immediate release nifedipine tablet taken once, 30 minutes pre-ET</offsets></p></list-item></list></p></sec><sec><label><offsets xml_i="17484" xml_f="17485" txt_i="9384" txt_f="9385">9</offsets></label><title><offsets xml_i="17500" xml_f="17515" txt_i="9385" txt_f="9400">Primary outcome</offsets></title><p><list list-type="simple"><list-item><label><offsets xml_i="17569" xml_f="17572" txt_i="9401" txt_f="9404">(1)</offsets></label><p><offsets xml_i="17583" xml_f="17679" txt_i="9404" txt_f="9497">IR, defined as the presence of serum human chorionic gonadotropic level &gt;5 IU/L following ET.</offsets></p></list-item><list-item><label><offsets xml_i="17713" xml_f="17716" txt_i="9498" txt_f="9501">(2)</offsets></label><p><offsets xml_i="17727" xml_f="17857" txt_i="9501" txt_f="9631">CPR, defined as the presence of a live pregnancy in the uterine cavity at a transvaginal ultrasound at 6 weeks’ gestation onwards.</offsets></p></list-item></list></p></sec><sec><label><offsets xml_i="17902" xml_f="17904" txt_i="9634" txt_f="9636">10</offsets></label><title><offsets xml_i="17919" xml_f="17936" txt_i="9636" txt_f="9653">Secondary outcome</offsets></title><p><list list-type="simple"><list-item><label><offsets xml_i="17990" xml_f="17993" txt_i="9654" txt_f="9657">(1)</offsets></label><p><offsets xml_i="18004" xml_f="18110" txt_i="9657" txt_f="9763">Adverse events defined as any unwanted outcomes, such as dizziness or hypotension, reported in this trial.</offsets></p></list-item><list-item><label><offsets xml_i="18144" xml_f="18147" txt_i="9764" txt_f="9767">(2)</offsets></label><p><offsets xml_i="18158" xml_f="18251" txt_i="9767" txt_f="9860">Miscarriage rate defined as loss of a diagnosed clinical pregnancy before 20 weeks gestation.</offsets></p></list-item><list-item><label><offsets xml_i="18285" xml_f="18288" txt_i="9861" txt_f="9864">(3)</offsets></label><p><offsets xml_i="18299" xml_f="18742" txt_i="9864" txt_f="10307">Pregnancy and neonatal outcomes including multiple pregnancy, congenital or chromosomal abnormalities, stillbirth, preeclampsia, delivery before 34 weeks, delivery between 34 and 37 weeks, necrotising enterocolitis, abnormal neurology, placenta praevia, gestational diabetes, low birth weight, admission to neonatal intensive care unit, duration of admission, need and duration of respiratory support, or any other neonatal morbidity reported.</offsets></p></list-item></list></p></sec><sec><label><offsets xml_i="18787" xml_f="18789" txt_i="10310" txt_f="10312">11</offsets></label><title><offsets xml_i="18804" xml_f="18815" txt_i="10312" txt_f="10323">Sample size</offsets></title><p><offsets xml_i="18826" xml_f="19233" txt_i="10324" txt_f="10731">As this is a small scale study, without precedence on which to base accurate power calculations, a power calculation has not been performed. This study should provide guidance for future larger randomized trials. We hypothesis that nifedipine will improve the IR and CPR after IVF/ICSI cycles. A convenient sample of 100 participants, 50 in each arm, was chosen to assess our primary and secondary outcomes.</offsets></p></sec><sec><label><offsets xml_i="19255" xml_f="19257" txt_i="10733" txt_f="10735">12</offsets></label><title><offsets xml_i="19272" xml_f="19290" txt_i="10735" txt_f="10753">Inclusion criteria</offsets></title><p><list list-type="simple"><list-item><label><offsets xml_i="19344" xml_f="19347" txt_i="10754" txt_f="10757">(1)</offsets></label><p><offsets xml_i="19358" xml_f="19445" txt_i="10757" txt_f="10844">A total of 18–45 year females undergoing IVF/ICSI cycles and fresh or frozen–thawed ET.</offsets></p></list-item><list-item><label><offsets xml_i="19479" xml_f="19482" txt_i="10845" txt_f="10848">(2)</offsets></label><p><offsets xml_i="19493" xml_f="19559" txt_i="10848" txt_f="10914">Baseline BP greater than or equal to 100/60 mm Hg measured pre-ET.</offsets></p></list-item></list></p></sec><sec><label><offsets xml_i="19604" xml_f="19606" txt_i="10917" txt_f="10919">13</offsets></label><title><offsets xml_i="19621" xml_f="19639" txt_i="10919" txt_f="10937">Exclusion criteria</offsets></title><p><list list-type="simple"><list-item><label><offsets xml_i="19693" xml_f="19696" txt_i="10938" txt_f="10941">(1)</offsets></label><p><offsets xml_i="19707" xml_f="19745" txt_i="10941" txt_f="10979">Body mass index (BMI) greater than 38.</offsets></p></list-item><list-item><label><offsets xml_i="19779" xml_f="19782" txt_i="10980" txt_f="10983">(2)</offsets></label><p><offsets xml_i="19793" xml_f="19881" txt_i="10983" txt_f="11068">Early follicular phase (day 2–4) serum follicle-stimulating hormone level &gt;20 mIU/mL.</offsets></p></list-item><list-item><label><offsets xml_i="19915" xml_f="19918" txt_i="11069" txt_f="11072">(3)</offsets></label><p><offsets xml_i="19929" xml_f="20010" txt_i="11072" txt_f="11153">Abnormal uterine cavity as evidenced by sonohysterogram or hysterosalpingography.</offsets></p></list-item><list-item><label><offsets xml_i="20044" xml_f="20047" txt_i="11154" txt_f="11157">(4)</offsets></label><p><offsets xml_i="20058" xml_f="20130" txt_i="11157" txt_f="11229">Any contraindication to being pregnant and carrying a pregnancy to term.</offsets></p></list-item><list-item><label><offsets xml_i="20164" xml_f="20167" txt_i="11230" txt_f="11233">(5)</offsets></label><p><offsets xml_i="20178" xml_f="20263" txt_i="11233" txt_f="11318">Contraindication for the use of nifedipine, estrogen, and progesterone suppositories.</offsets></p></list-item><list-item><label><offsets xml_i="20297" xml_f="20300" txt_i="11319" txt_f="11322">(6)</offsets></label><p><offsets xml_i="20311" xml_f="20559" txt_i="11322" txt_f="11570">Patient being treated with other drugs that interact with cytochrome P450 activity: azole antifungals, cimetidine, cyclosporine, erythromycin, quinidine, terfenadine, warfarin, benzodiazepines, flecainide, imipramine, propafenone, and theophylline.</offsets></p></list-item><list-item><label><offsets xml_i="20593" xml_f="20596" txt_i="11571" txt_f="11574">(7)</offsets></label><p><offsets xml_i="20607" xml_f="20701" txt_i="11574" txt_f="11668">Irregular heart beat or already being treated with another medication for high blood pressure.</offsets></p></list-item><list-item><label><offsets xml_i="20735" xml_f="20738" txt_i="11669" txt_f="11672">(8)</offsets></label><p><offsets xml_i="20749" xml_f="20860" txt_i="11672" txt_f="11783">Any ovarian or abdominal abnormality that may interfere with adequate transvaginal sonography (TVS) evaluation.</offsets></p></list-item><list-item><label><offsets xml_i="20894" xml_f="20897" txt_i="11784" txt_f="11787">(9)</offsets></label><p><offsets xml_i="20908" xml_f="20993" txt_i="11787" txt_f="11872">Administration of any investigational drugs within 3 months prior to study enrolment.</offsets></p></list-item><list-item><label><offsets xml_i="21027" xml_f="21031" txt_i="11873" txt_f="11877">(10)</offsets></label><p><offsets xml_i="21042" xml_f="21164" txt_i="11877" txt_f="11999">Patient not able to communicate adequately with the investigators and to comply with the requirements of the entire study.</offsets></p></list-item><list-item><label><offsets xml_i="21198" xml_f="21202" txt_i="12000" txt_f="12004">(11)</offsets></label><p><offsets xml_i="21213" xml_f="21260" txt_i="12004" txt_f="12051">Unwillingness to give written informed consent.</offsets></p></list-item><list-item><label><offsets xml_i="21294" xml_f="21298" txt_i="12052" txt_f="12056">(12)</offsets></label><p><offsets xml_i="21309" xml_f="21340" txt_i="12056" txt_f="12087">Previous entry into this study.</offsets></p></list-item><list-item><label><offsets xml_i="21374" xml_f="21378" txt_i="12088" txt_f="12092">(13)</offsets></label><p><offsets xml_i="21389" xml_f="21440" txt_i="12092" txt_f="12143">Baseline BP less than 100/60 mm Hg measured pre-ET.</offsets></p></list-item><list-item><label><offsets xml_i="21474" xml_f="21478" txt_i="12144" txt_f="12148">(14)</offsets></label><p><offsets xml_i="21489" xml_f="21550" txt_i="12148" txt_f="12209">Embryos that have undergone preimplantation genetic screening</offsets></p></list-item></list></p></sec><sec><label><offsets xml_i="21595" xml_f="21597" txt_i="12212" txt_f="12214">14</offsets></label><title><offsets xml_i="21612" xml_f="21628" txt_i="12214" txt_f="12230">Concomitant care</offsets></title><p><offsets xml_i="21639" xml_f="21774" txt_i="12231" txt_f="12366">Aside from trial protocol and inclusion criteria listed above, standard concomitant care, such as folic acid supplements, is permitted.</offsets></p></sec><sec><label><offsets xml_i="21796" xml_f="21798" txt_i="12368" txt_f="12370">15</offsets></label><title><offsets xml_i="21813" xml_f="21834" txt_i="12370" txt_f="12391">Participant enrolment</offsets></title><p><offsets xml_i="21845" xml_f="22260" txt_i="12392" txt_f="12807">This trial will begin recruitment at the level of infertility specialist. Once identified as requiring IVF/ICSI, and satisfying inclusion and criteria, the patient will be provided with detailed written information about the trial protocol. Once informed consent is obtained, then the patient will be randomized to one of the study arms and provided with the trial medication 30 minutes prior to their scheduled ET.</offsets></p></sec><sec><label><offsets xml_i="22282" xml_f="22284" txt_i="12809" txt_f="12811">16</offsets></label><title><offsets xml_i="22299" xml_f="22350" txt_i="12811" txt_f="12862">Allocation concealment, blinding, and randomization</offsets></title><p><offsets xml_i="22361" xml_f="22723" txt_i="12863" txt_f="13225">Randomization will be performed, by a research assistance, via a computer generated sequence in blocks of 10 recruited subjects. The allocation ratio into each arm will be 1:1. The randomization will be stratified for age into 2 groups: less than 35 years old and greater or equal to 35 years old. Neither patients nor caregivers will be aware of the allocation.</offsets></p><p><offsets xml_i="22730" xml_f="22904" txt_i="13226" txt_f="13400">All clinical staff will remain blinded to allocation of therapy until the statistical data base is cleaned and locked. Unblinding only be done in case of urgent medical need.</offsets></p></sec><sec><label><offsets xml_i="22926" xml_f="22928" txt_i="13402" txt_f="13404">17</offsets></label><title><offsets xml_i="22943" xml_f="22966" txt_i="13404" txt_f="13427">Adherence and retention</offsets></title><p><offsets xml_i="22977" xml_f="23436" txt_i="13428" txt_f="13887">To ensure the integrity of study data, participants adherence to trial protocol, that is, nifedipine administration, will be supervised by the clinical nurse. The time of drug administration, blood pressure pre- and post-ET, and the time of ET will be recorded on the patient record form. Every reasonable effort will be made from the time of enrolment until the end of follow-up to maintain contact with and maintain participant's participation in the trial.</offsets></p></sec><sec><label><offsets xml_i="23458" xml_f="23460" txt_i="13889" txt_f="13891">18</offsets></label><title><offsets xml_i="23475" xml_f="23488" txt_i="13891" txt_f="13904">Analysis plan</offsets></title><p><offsets xml_i="23499" xml_f="23663" txt_i="13905" txt_f="14069">Primary analysis will occur by the intention-to-treat principle. Statistical comparisons would be carried out using Chi-square test, Fisher exact test, and Student </offsets><italic><offsets xml_i="23671" xml_f="23672" txt_i="14069" txt_f="14070">t</offsets></italic><offsets xml_i="23681" xml_f="23786" txt_i="14070" txt_f="14175"> test with the Statistical Program for Social Science (SPSS, Inc., Version 23.0, Chicago, IL). A 2-sided </offsets><italic><offsets xml_i="23794" xml_f="23795" txt_i="14175" txt_f="14176">P</offsets></italic><offsets xml_i="23804" xml_f="24131" txt_i="14176" txt_f="14500"> &lt; .05 was taken as statistically significant. Primary and secondary outcomes between placebo group and treatment group would be analyzed using the above statistical comparisons. The baseline demographics of participants, such as age and number of embryo transferred, would also be analyzed to ensure adequate randomization.</offsets></p></sec><sec><label><offsets xml_i="24153" xml_f="24155" txt_i="14502" txt_f="14504">19</offsets></label><title><offsets xml_i="24170" xml_f="24215" txt_i="14504" txt_f="14549">Adverse events and data safety and monitoring</offsets></title><p><offsets xml_i="24226" xml_f="25368" txt_i="14550" txt_f="15692">During the treatment period, clinical care will remain unchanged and will be the responsibility of uninvolved medical staff. The principal investigators will be available by telephone at all times during the trial, and participants will be provided with contact details in case of any adverse events. Participants will also be screened at the time of their clinical visits, including ultrasound and oocyte collection appointments prior ET to ensure that patients are fit to participate in the research. Blood pressure and heart rate would be measured 30 minutes pre- and post-ET. If baseline blood pressure pre-ET is less than 100/60 mm Hg, participation in the study will not be allowed for safety purposes. Adverse events and side effects are recorded 30 minutes post-ET. Serious adverse events will be recorded separately and followed up until resolution. Such events will be reported to the principle investigators, Melbourne IVF research committee, Melbourne IVF Human Research Ethics Committee, Melbourne IVF quality management system, indemnity insurer, and if directed by HREC, to the Australian Therapeutics and Goods Administration.</offsets></p></sec><sec><label><offsets xml_i="25390" xml_f="25392" txt_i="15694" txt_f="15696">20</offsets></label><title><offsets xml_i="25407" xml_f="25445" txt_i="15696" txt_f="15734">Trial modification and discontinuation</offsets></title><p><offsets xml_i="25456" xml_f="25815" txt_i="15735" txt_f="16094">In the absence of adverse events, the medication regimen will not be modified once started. If other protocol changes are deemed necessary by the investigating team, ethical approval will be sought from approving Human Research Ethics Committee. Once approved, protocol amendments will be notified to all investigators, administrators, and trial participants.</offsets></p><p><offsets xml_i="25822" xml_f="26031" txt_i="16095" txt_f="16304">Patients are permitted to withdraw from study participation at any time. The trial will cease follow-up once patients have given birth or when clinical pregnancy is not detected from the trial treatment cycle.</offsets></p></sec><sec><label><offsets xml_i="26053" xml_f="26055" txt_i="16306" txt_f="16308">21</offsets></label><title><offsets xml_i="26070" xml_f="26130" txt_i="16308" txt_f="16368">Data collection, informed consent forms, and confidentiality</offsets></title><p><offsets xml_i="26141" xml_f="26777" txt_i="16369" txt_f="17005">Data will be recorded in hardcopy and electronic form. Hardcopies will be stored in a secured filing cabinet at the administering institution. Electronic copies will be stored on a password protected computer. Final trial dataset would only be accessible for this study's clinical investigators after recruitment and data collection has been completed. All data will be kept for 15 years; following this time, hardcopies will be destroyed by shredding or burning and electronic copies will be deleted by formatting. Participant records will not contain any directly identifiable information and no biological samples would be collected.</offsets></p></sec><sec><label><offsets xml_i="26799" xml_f="26801" txt_i="17007" txt_f="17009">22</offsets></label><title><offsets xml_i="26816" xml_f="26840" txt_i="17009" txt_f="17033">Ethics and dissemination</offsets></title><p><offsets xml_i="26851" xml_f="26997" txt_i="17034" txt_f="17180">Data analysis, interpretation, and conclusion will be presented at national and international conferences and published in peer-reviewed journals.</offsets></p></sec><sec><label><offsets xml_i="27019" xml_f="27021" txt_i="17182" txt_f="17184">23</offsets></label><title><offsets xml_i="27036" xml_f="27046" txt_i="17184" txt_f="17194">Discussion</offsets></title><p><offsets xml_i="27057" xml_f="27792" txt_i="17195" txt_f="17930">Implantation failure is a major factor limiting the success of IVF/ICSI treatment and excessive UCs is one of the mechanisms contributing to implantation failure. Given nifedipine's tocolytic properties, safety profile, and use in obstetrics practice, it is a promising candidate to improve the outcomes of IVF/ICSI treatment. This trial is essential to confirm the efficacy, side effects, and safety of nifedipine in infertility treatment. If this study confirms that nifedipine favors a positive outcome, we will then proceed to a phase II randomized controlled trial. A phase I trial to investigate the clinical benefits, namely improved implantation and pregnancy rate of nifedipine in IVF/ICSI treatment cycle, has been initiated.</offsets></p></sec></body><back><fn-group><fn fn-type="abbr"><p>Abbreviations: ART = assisted reproductive technology, CCB = calcium channel blocker, CPR = clinical pregnancy rate, ET = embryo transfer, ICSI = intracytoplasmic sperm injection, IR = implantation rate, IVF = in vitro fertilization, UC = uterine contraction.</p></fn><fn fn-type="presented-at"><p>Ethics and dissemination: Ethical approval has been obtained from Melbourne IVF Human Research Ethics Committee (36/14-MIVF). Data will be presented at academic conferences and published in peer-reviewed journals.</p></fn><fn fn-type="other"><p>Trial registration number: ACTRN12617000213347.</p></fn><fn fn-type="other"><p>Ethics approval: Ethical approval has been obtained from Melbourne IVF HREC (Ref: 36/14-MIVF).</p></fn><fn fn-type="other"><p>Authorship: The idea of the trial was conceived by AP and GR. AP, GR, and FA were involved in research design and primary writing of study protocol. KN was involved in the design and writing of the manuscript. KN, GR, TS, FA, and AP were involved in the trial design, writing, editing, and approval of the final manuscript.</p></fn><fn fn-type="financial-disclosure"><p>Funding/support: This work was supported both financially and in-kind by the Melbourne IVF Research Department who peer reviewed this study prior to the approval of funding. In-kind support was also afforded by The Department of Reproductive Services, Royal Women's Hospital.</p></fn><fn fn-type="COI-statement"><p>The authors have no conflicts of interest to disclose.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>[1]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sallam</surname><given-names>HN</given-names></name></person-group>
<article-title>Embryo transfer: factors involved in optimizing the success</article-title>. <source>Curr Opin Obstet Gynecol</source>
<year>2005</year>;<volume>17</volume>:<fpage>289</fpage>–<lpage>98</lpage>.<pub-id pub-id-type="pmid">15870564</pub-id></mixed-citation></ref><ref id="R2"><label>[2]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edwards</surname><given-names>RG</given-names></name></person-group>
<article-title>Clinical approaches to increasing uterine receptivity during human implantation</article-title>. <source>Hum Reprod</source>
<year>1995</year>;<volume>10</volume>:<fpage>60</fpage>–<lpage>6</lpage>.</mixed-citation></ref><ref id="R3"><label>[3]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paulson</surname><given-names>R</given-names></name><name><surname>Sauer</surname><given-names>M</given-names></name><name><surname>Lobo</surname><given-names>R</given-names></name></person-group>
<article-title>Factors affecting embryo implantation after human in vitro fertilization: a hypothesis</article-title>. <source>Am J Obstet Gynecol</source>
<year>1990</year>;<volume>163</volume>:<fpage>2020</fpage>–<lpage>3</lpage>.<pub-id pub-id-type="pmid">2256515</pub-id></mixed-citation></ref><ref id="R4"><label>[4]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tabibzadeh</surname><given-names>S</given-names></name><name><surname>Babaknia</surname><given-names>A</given-names></name></person-group>
<article-title>The signals and molecular pathways involved in implantation, a symbiotic interaction between blastocyst and endometrium involving adhesion and tissue invasion</article-title>. <source>Hum Reprod</source>
<year>1995</year>;<volume>10</volume>:<fpage>1579</fpage>–<lpage>602</lpage>.<pub-id pub-id-type="pmid">7593542</pub-id></mixed-citation></ref><ref id="R5"><label>[5]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fanchin</surname><given-names>R</given-names></name><name><surname>Righini</surname><given-names>C</given-names></name><name><surname>Olivennes</surname><given-names>F</given-names></name><etal></etal></person-group>
<article-title>Uterine contractions at the time of embryo transfer alter pregnancy rates after in-vitro fertilization</article-title>. <source>Hum Reprod</source>
<year>1998</year>;<volume>13</volume>:<fpage>1968</fpage>–<lpage>74</lpage>.<pub-id pub-id-type="pmid">9740459</pub-id></mixed-citation></ref><ref id="R6"><label>[6]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lesny</surname><given-names>P</given-names></name><name><surname>Killick</surname><given-names>SR</given-names></name><name><surname>Tetlow</surname><given-names>RL</given-names></name><etal></etal></person-group>
<article-title>Embryo transfer – can we learn anything new from the observation of junctional zone contractions?</article-title>
<source>Hum Reprod</source>
<year>1998</year>;<volume>13</volume>:<fpage>1540</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">9688388</pub-id></mixed-citation></ref><ref id="R7"><label>[7]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Che</surname><given-names>H</given-names></name><name><surname>Xiao</surname><given-names>L</given-names></name><etal></etal></person-group>
<article-title>Uterine peristalsis before embryo transfer affects the chance of clinical pregnancy in fresh and frozen-thawed embryo transfer cycles</article-title>. <source>Hum Reprod</source>
<year>2014</year>;<volume>29</volume>:<fpage>1238</fpage>–<lpage>43</lpage>.<pub-id pub-id-type="pmid">24664129</pub-id></mixed-citation></ref><ref id="R8"><label>[8]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernabeu</surname><given-names>R</given-names></name><name><surname>Roca</surname><given-names>M</given-names></name><name><surname>Torres</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>Indomethacin effect on implantation rates in oocyte recipients</article-title>. <source>Hum Reprod</source>
<year>2006</year>;<volume>21</volume>:<fpage>364</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">16284067</pub-id></mixed-citation></ref><ref id="R9"><label>[9]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fanchin</surname><given-names>R</given-names></name><name><surname>Righini</surname><given-names>C</given-names></name><name><surname>de Ziegler</surname><given-names>D</given-names></name><etal></etal></person-group>
<article-title>Effects of vaginal progesterone administration on uterine contractility at the time of embryo transfer</article-title>. <source>Fertil Steril</source>
<year>2001</year>;<volume>75</volume>:<fpage>1136</fpage>–<lpage>40</lpage>.<pub-id pub-id-type="pmid">11384639</pub-id></mixed-citation></ref><ref id="R10"><label>[10]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moon</surname><given-names>HS</given-names></name><name><surname>Park</surname><given-names>SH</given-names></name><name><surname>Lee</surname><given-names>JO</given-names></name><etal></etal></person-group>
<article-title>Treatment with piroxicam before embryo transfer increases the pregnancy rate after in vitro fertilization and embryo transfer</article-title>. <source>Fertil Steril</source>
<year>2004</year>;<volume>82</volume>:<fpage>816</fpage>–<lpage>20</lpage>.<pub-id pub-id-type="pmid">15482753</pub-id></mixed-citation></ref><ref id="R11"><label>[11]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinheiro</surname><given-names>O</given-names></name><name><surname>Cavagna</surname><given-names>M</given-names></name><name><surname>Baruffi</surname><given-names>R</given-names></name><etal></etal></person-group>
<article-title>Administration of β2-adrenergic agonists during the peri-implantation period does not improve implantation or pregnancy rates in intracytoplasmic sperm injection (ICSI) cycles</article-title>. <source>J Assist Reprod Genet</source>
<year>2003</year>;<volume>20</volume>:<fpage>513</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">15035551</pub-id></mixed-citation></ref><ref id="R12"><label>[12]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsirigotis</surname><given-names>M</given-names></name><name><surname>Pelekanos</surname><given-names>M</given-names></name><name><surname>Gilhespie</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>Ritodrine use during the peri-implantation period reduces uterine contractility and improves implantation and pregnancy rates post-IVF</article-title>. <source>Hum Reprod</source>
<year>2000</year>;<volume>15</volume>:<fpage>10</fpage>.</mixed-citation></ref><ref id="R13"><label>[13]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lan</surname><given-names>VTN</given-names></name><name><surname>Khang</surname><given-names>VN</given-names></name><name><surname>Nhu</surname><given-names>GH</given-names></name><etal></etal></person-group>
<article-title>Atosiban improves implantation and pregnancy rates in patients with repeated implantation failure</article-title>. <source>Reprod Biomed Online</source>
<year>2012</year>;<volume>25</volume>:<fpage>254</fpage>–<lpage>60</lpage>.<pub-id pub-id-type="pmid">22818095</pub-id></mixed-citation></ref><ref id="R14"><label>[14]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pierzynski</surname><given-names>P</given-names></name></person-group>
<article-title>Oxytocin and vasopressin V<sub>1A</sub> receptors as new therapeutic targets in assisted reproduction</article-title>. <source>Reprod Biomed Online</source>
<year>2011</year>;<volume>22</volume>:<fpage>9</fpage>–<lpage>16</lpage>.<pub-id pub-id-type="pmid">21130036</pub-id></mixed-citation></ref><ref id="R15"><label>[15]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>E</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><etal></etal></person-group>
<article-title>A randomized double blind comparison of atosiban in patients undergoing IVF treatment</article-title>. <source>Hum Reprod</source>
<year>2014</year>;<volume>29</volume>:<fpage>2687</fpage>–<lpage>94</lpage>.<pub-id pub-id-type="pmid">25336707</pub-id></mixed-citation></ref><ref id="R16"><label>[16]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Han</surname><given-names>E</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>Efficacy of oxytocin antagonist infusion in improving <italic>in vitro</italic> fertilization outcomes on the day of embryo transfer: a meta-analysis</article-title>. <source>Clin Exp Reprod Med</source>
<year>2016</year>;<volume>43</volume>:<fpage>233</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">28090463</pub-id></mixed-citation></ref><ref id="R17"><label>[17]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kido</surname><given-names>A</given-names></name><name><surname>Togashi</surname><given-names>K</given-names></name><name><surname>Hatayama</surname><given-names>H</given-names></name><etal></etal></person-group>
<article-title>Uterine peristalsis in women with repeated IVF failures: possible therapeutic effect of hyoscine bromide</article-title>. <source>J Obstet Gynaecol Can</source>
<year>2009</year>;<volume>31</volume>:<fpage>732</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="pmid">19772706</pub-id></mixed-citation></ref><ref id="R18"><label>[18]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><etal></etal></person-group>
<article-title>Inhibition of endometrial fundocervical wave by phloroglucinol and the outcome of in vitro fertilization</article-title>. <source>Reprod Biol</source>
<year>2013</year>;<volume>13</volume>:<fpage>88</fpage>–<lpage>91</lpage>.<pub-id pub-id-type="pmid">23522076</pub-id></mixed-citation></ref><ref id="R19"><label>[19]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baruffi</surname><given-names>R</given-names></name><name><surname>Mauri</surname><given-names>A</given-names></name><name><surname>Petersen</surname><given-names>C</given-names></name><etal></etal></person-group>
<article-title>Effects of vaginal progesterone administration starting on the day of oocyte retrieval on pregnancy rates</article-title>. <source>J Assist Reprod Genet</source>
<year>2003</year>;<volume>20</volume>:<fpage>517</fpage>–<lpage>20</lpage>.<pub-id pub-id-type="pmid">15035552</pub-id></mixed-citation></ref><ref id="R20"><label>[20]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakai</surname><given-names>A</given-names></name><name><surname>Togashi</surname><given-names>K</given-names></name><name><surname>Kosaka</surname><given-names>K</given-names></name><etal></etal></person-group>
<article-title>Do anticholinergic agents suppress uterine peristalsis and sporadic myometrial contractions at cine MR imaging?</article-title>
<source>Radiology</source>
<year>2008</year>;<volume>246</volume>:<fpage>489</fpage>–<lpage>96</lpage>.<pub-id pub-id-type="pmid">18094262</pub-id></mixed-citation></ref><ref id="R21"><label>[21]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wada</surname><given-names>I</given-names></name><name><surname>Hsu</surname><given-names>C</given-names></name><name><surname>Williams</surname><given-names>G</given-names></name><etal></etal></person-group>
<article-title>The benefits of low-dose aspirin therapy in women with impaired uterine perfusion during assisted conception</article-title>. <source>Hum Reprod</source>
<year>1994</year>;<volume>9</volume>:<fpage>1954</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">7844233</pub-id></mixed-citation></ref><ref id="R22"><label>[22]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weckstein</surname><given-names>L</given-names></name><name><surname>Jacobson</surname><given-names>A</given-names></name><name><surname>Galen</surname><given-names>D</given-names></name><etal></etal></person-group>
<article-title>Low-dose aspirin for oocyte donation recipients with a thin endometrium: prospective, randomized study</article-title>. <source>Fertil Steril</source>
<year>1997</year>;<volume>68</volume>:<fpage>927</fpage>–<lpage>30</lpage>.<pub-id pub-id-type="pmid">9389827</pub-id></mixed-citation></ref><ref id="R23"><label>[23]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubinstein</surname><given-names>M</given-names></name><name><surname>Marazzi</surname><given-names>A</given-names></name><name><surname>Fried</surname><given-names>E</given-names></name></person-group>
<article-title>Low-dose aspirin treatment improves ovarian responsiveness, uterine and ovarian blood flow velocity, implantation, and pregnancy rates in patients undergoing in vitro fertilization: a prospective, randomized, double-blind placebo-controlled assay</article-title>. <source>Fertil Steril</source>
<year>1999</year>;<volume>71</volume>:<fpage>825</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">10231040</pub-id></mixed-citation></ref><ref id="R24"><label>[24]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amro</surname><given-names>FH</given-names></name><name><surname>Moussa</surname><given-names>HN</given-names></name><name><surname>Ashimi</surname><given-names>OA</given-names></name><etal></etal></person-group>
<article-title>Treatment options for hypertension in pregnancy and puerperium</article-title>. <source>Expert Opin Drug Saf</source>
<year>2016</year>;<volume>15</volume>:<fpage>1635</fpage>–<lpage>42</lpage>.<pub-id pub-id-type="pmid">27689239</pub-id></mixed-citation></ref><ref id="R25"><label>[25]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oei</surname><given-names>SG</given-names></name></person-group>
<article-title>Calcium channel blockers for tocolysis: a review of their role and safety following reports of serious adverse events</article-title>. <source>Eur J Obstet Gynecol Reprod Biol</source>
<year>2016</year>;<volume>126</volume>:<fpage>136</fpage>–<lpage>45</lpage>.</mixed-citation></ref><ref id="R26"><label>[26]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nayler</surname><given-names>WG</given-names></name><name><surname>Poole-Wilson</surname><given-names>P</given-names></name></person-group>
<article-title>Calcium antagonists: definition and mode of action</article-title>. <source>Basic Res Cardiol</source>
<year>1981</year>;<volume>76</volume>:<fpage>1</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="pmid">6112981</pub-id></mixed-citation></ref><ref id="R27"><label>[27]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamont</surname><given-names>CD</given-names></name><name><surname>Jørgensen</surname><given-names>JS</given-names></name><name><surname>Lamont</surname><given-names>RF</given-names></name></person-group>
<article-title>The safety of tocolytics used for the inhibition of preterm labour</article-title>. <source>Expert Opin Drug Saf</source>
<year>2016</year>;<volume>15</volume>:<fpage>1163</fpage>–<lpage>73</lpage>.<pub-id pub-id-type="pmid">27159501</pub-id></mixed-citation></ref><ref id="R28"><label>[28]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>K</given-names></name><name><surname>Zamora</surname><given-names>J</given-names></name><name><surname>Lamont</surname><given-names>RF</given-names></name><etal></etal></person-group>
<article-title>Safety concerns for the use of calcium channel blockers in pregnancy for the treatment of spontaneous preterm labour and hypertension: a systematic review and meta-regression analysis</article-title>. <source>J Maternal Fetal Neonatal Med</source>
<year>2010</year>;<volume>23</volume>:<fpage>1030</fpage>–<lpage>8</lpage>.</mixed-citation></ref><ref id="R29"><label>[29]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Geijn</surname><given-names>HP</given-names></name><name><surname>Lenglet</surname><given-names>JE</given-names></name><name><surname>Bolte</surname><given-names>AC</given-names></name></person-group>
<article-title>Nifedipine trials: effectiveness and safety aspects</article-title>. <source>Br J Obstet Gynaecol</source>
<year>2005</year>;<volume>112</volume>:<fpage>79</fpage>–<lpage>83</lpage>.</mixed-citation></ref><ref id="R30"><label>[30]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsatsaris</surname><given-names>V</given-names></name><name><surname>Cabrol</surname><given-names>D</given-names></name><name><surname>Carbonne</surname><given-names>B</given-names></name></person-group>
<article-title>Pharmacokinetics of tocolytic agents</article-title>. <source>Clin Pharmacokinet</source>
<year>2004</year>;<volume>43</volume>:<fpage>833</fpage>–<lpage>44</lpage>.<pub-id pub-id-type="pmid">15509182</pub-id></mixed-citation></ref><ref id="R31"><label>[31]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>SM</given-names></name><name><surname>Dunn</surname><given-names>HE</given-names></name><name><surname>Hankins</surname><given-names>GD</given-names></name></person-group>
<article-title>A review of oral labetalol and nifedipine in mild to moderate hypertension in pregnancy</article-title>. <source>Semin Perinatol</source>
<year>2015</year>;<volume>39</volume>:<fpage>548</fpage>–<lpage>55</lpage>.<pub-id pub-id-type="pmid">26344738</pub-id></mixed-citation></ref><ref id="R32"><label>[32]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conde-Agudelo</surname><given-names>A</given-names></name><name><surname>Romero</surname><given-names>R</given-names></name><name><surname>Kusanovic</surname><given-names>JP</given-names></name></person-group>
<article-title>Nifedipine in the management of preterm labor: a systematic review and metaanalysis</article-title>. <source>Am J Obstet Gynecol</source>
<year>2011</year>;<volume>204</volume>:<fpage>134.e1-20</fpage>.<pub-id pub-id-type="pmid">21284967</pub-id></mixed-citation></ref><ref id="R33"><label>[33]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shekhar</surname><given-names>S</given-names></name><name><surname>Gupta</surname><given-names>N</given-names></name><name><surname>Kirubakaran</surname><given-names>R</given-names></name><etal></etal></person-group>
<article-title>Oral nifedipine versus intravenous labetalol for severe hypertension during pregnancy: a systematic review and meta-analysis</article-title>. <source>BJOG</source>
<year>2016</year>;<volume>123</volume>:<fpage>40</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">26113232</pub-id></mixed-citation></ref><ref id="R34"><label>[34]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamasato</surname><given-names>K</given-names></name><name><surname>Burlingame</surname><given-names>J</given-names></name><name><surname>Kaneshiro</surname><given-names>B</given-names></name></person-group>
<article-title>Hemodynamic effects of nifedipine tocolysis</article-title>. <source>J Obstet Gynaecol Res</source>
<year>2015</year>;<volume>41</volume>:<fpage>17</fpage>–<lpage>22</lpage>.<pub-id pub-id-type="pmid">25164435</pub-id></mixed-citation></ref><ref id="R35"><label>[35]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cornette</surname><given-names>J</given-names></name><name><surname>Duvekot</surname><given-names>JJ</given-names></name><name><surname>Roos-Hesselink</surname><given-names>JW</given-names></name><etal></etal></person-group>
<article-title>Maternal and fetal haemodynamic effects of nifedipine in normotensive pregnant women</article-title>. <source>BJOG</source>
<year>2011</year>;<volume>118</volume>:<fpage>510</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="pmid">21219592</pub-id></mixed-citation></ref><ref id="R36"><label>[36]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klauser</surname><given-names>CK</given-names></name><name><surname>Briery</surname><given-names>CM</given-names></name><name><surname>Martin</surname><given-names>RW</given-names></name><etal></etal></person-group>
<article-title>A comparison of three tocolytics for preterm labor: a randomized clinical trial</article-title>. <source>J Maternal Fetal Neonatal Med</source>
<year>2014</year>;<volume>27</volume>:<fpage>801</fpage>–<lpage>6</lpage>.</mixed-citation></ref><ref id="R37"><label>[37]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saleh</surname><given-names>SS</given-names></name><name><surname>Al-Ramahi</surname><given-names>MQ</given-names></name><name><surname>Al Kazaleh</surname><given-names>FA</given-names></name></person-group>
<article-title>Atosiban and nifedipine in the suppression of pre- term labour: a comparative study</article-title>. <source>J Obstet Gynaecol</source>
<year>2013</year>;<volume>33</volume>:<fpage>43</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="pmid">23259877</pub-id></mixed-citation></ref><ref id="R38"><label>[38]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scholz</surname><given-names>H</given-names></name></person-group>
<article-title>Pharmacological aspects of calcium channel blockers</article-title>. <source>Cardiovasc Drugs Ther</source>
<year>1997</year>;<volume>10</volume>:<fpage>869</fpage>–<lpage>72</lpage>.<pub-id pub-id-type="pmid">9126675</pub-id></mixed-citation></ref><ref id="R39"><label>[39]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Higby</surname><given-names>K</given-names></name><name><surname>Xenakis</surname><given-names>EM</given-names></name><name><surname>Pauerstein</surname><given-names>CJ</given-names></name></person-group>
<article-title>Do tocolytic agents stop preterm labor? A critical and comprehensive review of efficacy and safety</article-title>. <source>Am J Obstet Gynecol</source>
<year>1993</year>;<volume>168</volume>:<fpage>1247</fpage>–<lpage>59</lpage>.<pub-id pub-id-type="pmid">8097367</pub-id></mixed-citation></ref><ref id="R40"><label>[40]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamat</surname><given-names>S</given-names></name><name><surname>Veena</surname><given-names>P</given-names></name><name><surname>Rani</surname><given-names>R</given-names></name></person-group>
<article-title>Comparison of nifedipine and progesterone for maintenance tocolysis after arrested preterm labour</article-title>. <source>J Obstet Gynaecol</source>
<year>2014</year>;<volume>34</volume>:<fpage>322</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="pmid">24483757</pub-id></mixed-citation></ref><ref id="R41"><label>[41]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papatsonis</surname><given-names>DN</given-names></name><name><surname>Van Geijn</surname><given-names>HP</given-names></name><name><surname>Adèr</surname><given-names>HJ</given-names></name><etal></etal></person-group>
<article-title>Nifedipine and ritodrine in the management of preterm labor: a randomized multicenter trial</article-title>. <source>Obstet Gynecol</source>
<year>1997</year>;<volume>90</volume>:<fpage>230</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="pmid">9241299</pub-id></mixed-citation></ref><ref id="R42"><label>[42]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pryde</surname><given-names>PG</given-names></name><name><surname>Besinger</surname><given-names>RE</given-names></name><name><surname>Gianopoulos</surname><given-names>JG</given-names></name><etal></etal></person-group>
<article-title>Adverse and beneficial effects of tocolytic therapy</article-title>. <source>Semin Perinatol</source>
<year>2001</year>;<volume>25</volume>:<fpage>316</fpage>–<lpage>40</lpage>.<pub-id pub-id-type="pmid">11707019</pub-id></mixed-citation></ref><ref id="R43"><label>[43]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harake</surname><given-names>B</given-names></name><name><surname>Gilbert</surname><given-names>RD</given-names></name><name><surname>Ashwal</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>Nifedipine: effects on fetal and maternal hemodynamics in pregnant sheep</article-title>. <source>Am J Obstet Gynecol</source>
<year>1987</year>;<volume>157</volume><issue>(4 Pt 1)</issue>:<fpage>1003</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">3674140</pub-id></mixed-citation></ref><ref id="R44"><label>[44]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holbrook</surname><given-names>RH</given-names><suffix>Jr</suffix></name><name><surname>Lirette</surname><given-names>M</given-names></name><name><surname>Katz</surname><given-names>M</given-names></name></person-group>
<article-title>Cardiovascular and tocolytic effects of nicardipine HCl in the pregnant rabbit: comparison with ritodrine HCl</article-title>. <source>Obstet Gynecol</source>
<year>1987</year>;<volume>69</volume>:<fpage>83</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">3796925</pub-id></mixed-citation></ref><ref id="R45"><label>[45]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parisi</surname><given-names>VM</given-names></name><name><surname>Salinas</surname><given-names>J</given-names></name><name><surname>Stockmar</surname><given-names>EJ</given-names></name></person-group>
<article-title>Fetal vascular responses to maternal nicardipine administration in the hypertensive ewe</article-title>. <source>Am J Obstet Gynecol</source>
<year>1989</year>;<volume>161</volume>:<fpage>1035</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">2801819</pub-id></mixed-citation></ref><ref id="R46"><label>[46]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuda</surname><given-names>Y</given-names></name><name><surname>Ikenoue</surname><given-names>T</given-names></name><name><surname>Matsuda</surname><given-names>K</given-names></name><etal></etal></person-group>
<article-title>The effect of nicardipine on maternal and fetal hemodynamics and uterine blood flow in chronically instrumented pregnant goats</article-title>. <source>Asia Oceania J Obstet Gynaecol</source>
<year>1993</year>;<volume>19</volume>:<fpage>191</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">8379868</pub-id></mixed-citation></ref><ref id="R47"><label>[47]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bortolus</surname><given-names>R</given-names></name><name><surname>Ricci</surname><given-names>E</given-names></name><name><surname>Chatenoud</surname><given-names>L</given-names></name><etal></etal></person-group>
<article-title>Nifedipine administered in pregnancy: effect on the development of children at 18 months</article-title>. <source>Br J Obstet Gynaecol</source>
<year>2000</year>;<volume>107</volume>:<fpage>792</fpage>–<lpage>4</lpage>.</mixed-citation></ref><ref id="R48"><label>[48]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sorensen</surname><given-names>HT</given-names></name><name><surname>Czeizel</surname><given-names>AE</given-names></name><name><surname>Rockenbauer</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>The risk of limb deficiencies and other congenital abnormalities in children exposed in utero to calcium channel blockers</article-title>. <source>Acta Ohstet Gynecol Scand</source>
<year>2001</year>;<volume>80</volume>:<fpage>397</fpage>–<lpage>401</lpage>.</mixed-citation></ref><ref id="R49"><label>[49]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Economy</surname><given-names>KE</given-names></name><name><surname>Abuhamad</surname><given-names>AZ</given-names></name></person-group>
<article-title>Calcium channel blockers as tocolytics</article-title>. <source>Semin Perinatol</source>
<year>2001</year>;<volume>25</volume>:<fpage>264</fpage>–<lpage>71</lpage>.<pub-id pub-id-type="pmid">11707015</pub-id></mixed-citation></ref><ref id="R50"><label>[50]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mercer</surname><given-names>BM</given-names></name><name><surname>Merlino</surname><given-names>AA</given-names></name></person-group>
<article-title>Magnesium sulfate for preterm labor and preterm birth</article-title>. <source>Obstet Gynecol</source>
<year>2009</year>;<volume>114</volume>:<fpage>650</fpage>–<lpage>68</lpage>.<pub-id pub-id-type="pmid">19701047</pub-id></mixed-citation></ref><ref id="R51"><label>[51]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsatsaris</surname><given-names>V</given-names></name><name><surname>Papatsonis</surname><given-names>D</given-names></name><name><surname>Goffinet</surname><given-names>F</given-names></name><etal></etal></person-group>
<article-title>Tocolysis with nifedipine or beta-adrenergic agonists: a meta-analsis</article-title>. <source>Obstet Gynecol</source>
<year>2001</year>;<volume>97</volume>:<fpage>840</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">11336775</pub-id></mixed-citation></ref><ref id="R52"><label>[52]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papatsonis</surname><given-names>DN</given-names></name><name><surname>Kok</surname><given-names>JH</given-names></name><name><surname>van Geijn</surname><given-names>HP</given-names></name><etal></etal></person-group>
<article-title>Neonatal effects of nifedipine and ritodrine for preterm labor</article-title>. <source>Obstet Gynecol</source>
<year>2000</year>;<volume>95</volume>:<fpage>477</fpage>–<lpage>81</lpage>.<pub-id pub-id-type="pmid">10725475</pub-id></mixed-citation></ref><ref id="R53"><label>[53]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coomarasamy</surname><given-names>A</given-names></name><name><surname>Knox</surname><given-names>EM</given-names></name><name><surname>Gee</surname><given-names>H</given-names></name><etal></etal></person-group>
<article-title>Effectiveness of nifedipine versus atosiban for tocolysis in preterm labour: a meta- analysis with an indirect comparison of randomised trials</article-title>. <source>BJOG</source>
<year>2003</year>;<volume>110</volume>:<fpage>1045</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">14664874</pub-id></mixed-citation></ref><ref id="R54"><label>[54]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abramovici</surname><given-names>A</given-names></name><name><surname>Cantu</surname><given-names>J</given-names></name><name><surname>Jenkins</surname><given-names>SM</given-names></name></person-group>
<article-title>Tocolytic therapy for acute preterm labor</article-title>. <source>Obstet Gynecol Clin North Am</source>
<year>2012</year>;<volume>39</volume>:<fpage>77</fpage>–<lpage>87</lpage>.<pub-id pub-id-type="pmid">22370109</pub-id></mixed-citation></ref><ref id="R55"><label>[55]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conde-Agudelo</surname><given-names>A</given-names></name><name><surname>Papageorghiou</surname><given-names>AT</given-names></name><name><surname>Kennedy</surname><given-names>SH</given-names></name><etal></etal></person-group>
<article-title>Novel biomarkers for the prediction of the spontaneous preterm birth phenotype: a systematic review and meta-analysis</article-title>. <source>BJOG</source>
<year>2011</year>;<volume>118</volume>:<fpage>1042</fpage>–<lpage>54</lpage>.<pub-id pub-id-type="pmid">21401853</pub-id></mixed-citation></ref><ref id="R56"><label>[56]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Heus</surname><given-names>R</given-names></name><name><surname>Mulder</surname><given-names>EJ</given-names></name><name><surname>Visser</surname><given-names>GH</given-names></name></person-group>
<article-title>Management of preterm labor: atosiban or nifedipine?</article-title>
<source>Int J Womens Health</source>
<year>2010</year>;<volume>2</volume>:<fpage>137</fpage>–<lpage>42</lpage>.<pub-id pub-id-type="pmid">21072306</pub-id></mixed-citation></ref></ref-list></back></article>